Cho William C S, Yip Tai-Tung, Chung Wai-Shing, Lee Sally K W, Leung Albert W N, Cheng Christopher H K, Yue Kevin K M
School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong, China.
J Ethnopharmacol. 2006 Nov 24;108(2):272-9. doi: 10.1016/j.jep.2006.05.009. Epub 2006 May 20.
Diabetes mellitus (DM) is now a global health problem, however, its pathogenesis has not yet been fully deciphered. Even though modern medicine has great contribution to the control and treatment of DM, it is still far from success to completely cure the disease. Panax ginseng C.A. Meyer (ginseng) is a well-recognized traditional Chinese medicine for treating DM in Asia. In this study, high throughput proteomic approach has been adopted to investigate the antidiabetic action of 2 weeks' ginsenoside Re (Re, a major component of ginseng) administration to streptozotocin-induced diabetic rats. Employing surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) and bioinformatics, 432 cluster peaks were detected in the samples, among them 293 potential biomarkers were found to have significant differentiations between the DM and control normal rats. When the Re-treated diabetic rats were compared to the untreated ones, a protein peak was detected to have significant alteration corresponding to Re treatment. This specific protein was found to match with C-reactive protein (CRP) in the protein database, and was subsequently validated by ELISA. This is the first study demonstrated that CRP could be altered by Re treatment, indicating that Re may improve diabetes and its complications by alleviation of inflammation.
糖尿病(DM)如今是一个全球性的健康问题,然而,其发病机制尚未完全破解。尽管现代医学对糖尿病的控制和治疗有很大贡献,但要完全治愈该疾病仍远未成功。人参(Panax ginseng C.A. Meyer)是亚洲公认的治疗糖尿病的传统中药。在本研究中,采用高通量蛋白质组学方法来研究对链脲佐菌素诱导的糖尿病大鼠连续2周给予人参皂苷Re(Re,人参的主要成分)的抗糖尿病作用。利用表面增强激光解吸/电离飞行时间质谱(SELDI-TOF MS)和生物信息学,在样本中检测到432个聚类峰,其中发现293个潜在生物标志物在糖尿病大鼠和对照正常大鼠之间有显著差异。当将接受Re治疗的糖尿病大鼠与未治疗的大鼠进行比较时,检测到一个蛋白质峰因Re治疗而有显著变化。在蛋白质数据库中发现这个特定蛋白质与C反应蛋白(CRP)匹配,随后通过酶联免疫吸附测定(ELISA)进行了验证。这是第一项证明CRP可因Re治疗而改变的研究,表明Re可能通过减轻炎症来改善糖尿病及其并发症。